{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:08:31Z","timestamp":1790312911549,"version":"4.1.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Medication-related osteonecrosis of the jaw (MRONJ) poses a significant challenge considering the absence of a \u201cgold standard\u201d treatment. Cell-based therapy and tissue engineering offer promising therapeutic alternatives. This study aimed to harness the regenerative properties of adipose-tissue stromal vascular fraction (AT-SVF) and leukocyte-platelet-rich fibrin (L-PRF) for MRONJ treatment. AT-SVF contains mesenchymal stromal cells (MSC) and endothelial progenitor cells (EPC), which promote bone formation, while the L-PRF scaffold can serve as a three-dimensional scaffold for the AT-SVF and support tissue healing through growth factor release.<\/jats:p><jats:p><jats:bold>Materials and methods:<\/jats:bold> The protocol involved applying autologous AT-SVF within an L-PRF matrix following surgical debridement. Age, gender, body mass index, comorbidities, underlying oncological condition, prescribed antiresorptive treatment: BP or DMB, antiresorptive treatment duration, antiresorptive treatment potential discontinuation, number of MRONJ lesion, MRONJ location, MRONJ stage, MRONJ trigger factor were assessed for each patient. Patients underwent the procedure and were monitored for a minimum of 6\u00a0months based on clinical, biological and medical imaging criteria.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Nine patients, with a total of ten MRONJ lesions, participated in the study. Six patients were female, and three were male, with a mean age of 68 \u00b1 8\u00a0years. Four patients had multiple myeloma (MM), three had metastatic breast cancer, and two had metastatic prostate cancer. Seven MRONJ cases were classified as stage II, and three were classified as stage III. Soft tissue completely healed within a month after treatment in nine cases, with no clinical improvement observed in the remaining case. During follow-up, no sign of MRONJ recurrence was observed. Tridimensional medical imaging revealed bone healing 6\u00a0months after the surgical procedure. Immunophenotyping confirmed the presence of MSC and EPC in the AT-SVF: 12,6 \u00b1 4,5% CD31<jats:sup>+<\/jats:sup>, 20.5 \u00b1 7,8% CD34<jats:sup>+<\/jats:sup>, 34,4 \u00b1 7,3% CD146<jats:sup>+<\/jats:sup> and 54,6 \u00b1 7,4% CD45<jats:sup>+<\/jats:sup>.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This prospective study introduces a potential new treatment approach for MRONJ using autologous AT-SVF within an L-PRF scaffold. Our results are encouraging and suggest the need for further investigation with a larger patient cohort to better understand the underlying mechanisms.<\/jats:p>","DOI":"10.3389\/fcell.2024.1338376","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:28:18Z","timestamp":1706243298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of medication-related osteonecrosis of the jaw with cell therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Cyril Lucien","family":"Bouland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokneddine","family":"Javadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Yanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Le Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mestrallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelianos","family":"Kampouridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lalmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Vanden Eynden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Boutremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Dequanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Philippart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lagneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"B1","first-page":"1741","article-title":"Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00262-014-1623-y","article-title":"Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells","volume":"64","author":"Andr\u00e9","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jcms.2015.04.026","article-title":"Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model","volume":"43","author":"Barba-Recreo","year":"2015","journal-title":"J. Craniomaxillofac Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jormas.2020.05.024","article-title":"Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF","volume":"122","author":"Bouland","year":"","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"674084","DOI":"10.3389\/fcell.2021.674084","article-title":"Cross-talk between mesenchymal stromal cells (MSCs) and endothelial progenitor cells (EPCs) in bone regeneration","volume":"9","author":"Bouland","year":"","journal-title":"Front. Cell Dev. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116144","DOI":"10.1016\/j.bone.2021.116144","article-title":"Engineered osteoclasts resorb necrotic alveolar bone in anti-RANKL antibody-treated mice","volume":"153","author":"Buranaphatthana","year":"2021","journal-title":"Bone"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.3390\/ijerph17165998","article-title":"Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1746-160X-7-16","article-title":"Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw","volume":"7","author":"Cella","year":"2011","journal-title":"Head. Face Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.15283\/ijsc.2009.2.2.122","article-title":"Adult stem cell therapy for autoimmune disease","volume":"2","author":"Choi","year":"2009","journal-title":"Int. J. Stem Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.3390\/jcm12144662","article-title":"Outcomes of a pharmacological protocol with pentoxifylline and tocopherol for the management of medication-related osteonecrosis of the jaws (MRONJ): a randomized study on 202 osteoporosis patients","volume":"12","author":"Colapinto","year":"2023","journal-title":"J. Clin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/0284186X.2020.1730004","article-title":"Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases","volume":"59","author":"De Santis","year":"2020","journal-title":"Acta Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.3390\/jcm11185307","article-title":"Ozone infiltration for osteonecrosis of the jaw therapy: a case series","volume":"11","author":"Di Fede","year":"2022","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/09537104.2017.1293812","article-title":"The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane","volume":"29","author":"Dohan Ehrenfest","year":"2018","journal-title":"Platelets"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e929684","DOI":"10.12659\/MSM.929684","article-title":"Exosomes from adipose-derived stem cells can prevent medication-related osteonecrosis of the jaw","volume":"27","author":"Dong","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"B15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/pharmaceutics15020558","article-title":"Potential of mesenchymal stromal cell-derived extracellular vesicles as natural nanocarriers: concise review","volume":"15","author":"Draguet","year":"","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/cancers15112901","article-title":"Extracellular vesicles derived from human umbilical cord mesenchymal stromal cells as an efficient nanocarrier to deliver siRNA or drug to pancreatic cancer cells","volume":"15","author":"Draguet","year":"","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrd3978","article-title":"Extracellular vesicles: biology and emerging therapeutic opportunities","volume":"12","author":"El Andaloussi","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4173578","DOI":"10.1155\/2020\/4173578","article-title":"Functional comparison between healthy and multiple myeloma adipose stromal cells","volume":"2020","author":"Espagnolle","year":"2020","journal-title":"Stem Cells Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.reth.2023.08.003","article-title":"Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: a systematic review and proposed reporting guidelines (CLINIC-STRA-SVF)","volume":"24","author":"Ferreira","year":"2023","journal-title":"Regen. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jcms.2020.01.014","article-title":"Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review","volume":"48","author":"Fortunato","year":"2020","journal-title":"J. Craniomaxillofac Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.joms.2008.12.003","article-title":"Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Freiberger","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1200\/JOP.19.00645","article-title":"Comment on medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline summary","volume":"16","author":"Fusco","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1097\/SCS.0b013e3182869968","article-title":"Cell therapy in bisphosphonate-related osteonecrosis of the jaw","volume":"24","author":"Gonz\u00e1lvez-Garc\u00eda","year":"2013","journal-title":"J. Craniofac Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"115676","DOI":"10.1016\/j.bone.2020.115676","article-title":"Adjuvant therapies for MRONJ: a systematic review","volume":"141","author":"Govaerts","year":"2020","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ijom.2019.07.016","article-title":"Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"49","author":"Guo","year":"2020","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13287-018-1115-7","article-title":"Exosomes secreted by endothelial progenitor cells accelerate bone regeneration during distraction osteogenesis by stimulating angiogenesis","volume":"10","author":"Jia","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/biores.2013.0024","article-title":"One-step surgical procedure for the treatment of osteochondral defects with adipose-derived stem cells in a caprine knee defect: a pilot study","volume":"2","author":"Jurgens","year":"2013","journal-title":"Biores Open Access"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101072","DOI":"10.1016\/j.bonr.2021.101072","article-title":"The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: a 12-year retrospective study of 129 patients","volume":"14","author":"Kaibuchi","year":"2021","journal-title":"Bone Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"902349","DOI":"10.3389\/fbioe.2022.902349","article-title":"Novel cell therapy using mesenchymal stromal cell sheets for medication-related osteonecrosis of the jaw","volume":"10","author":"Kaibuchi","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.reth.2018.10.008","article-title":"Allogeneic multipotent mesenchymal stromal cell sheet transplantation promotes healthy healing of wounds caused by zoledronate and dexamethasone in canine mandibular bones","volume":"10","author":"Kaibuchi","year":"2019","journal-title":"Regen. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.actbio.2016.06.022","article-title":"Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model","volume":"42","author":"Kaibuchi","year":"2016","journal-title":"Acta Biomater."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J. Bone Min. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13287-019-1308-8","article-title":"Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice","volume":"10","author":"Kuroshima","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/jbmr.3292","article-title":"Transplantation of noncultured stromal vascular fraction cells of adipose tissue ameliorates osteonecrosis of the jaw-like lesions in mice","volume":"33","author":"Kuroshima","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13104-021-05900-5","article-title":"Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid","volume":"15","author":"Li","year":"2022","journal-title":"BMC Res. Notes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1089\/scd.2012.0615","article-title":"Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine","volume":"22","author":"Li","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e94395","DOI":"10.1371\/journal.pone.0094395","article-title":"The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/term.1617","article-title":"Review of vascularised bone tissue-engineering strategies with a focus on co-culture systems","volume":"9","author":"Liu","year":"2015","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/JPER.18-0553","article-title":"Standardization of relative centrifugal forces in studies related to platelet-rich fibrin","volume":"90","author":"Miron","year":"2019","journal-title":"Periodontol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fbioe.2020.00307","article-title":"Successful use of human AB serum to support the expansion of adipose tissue-derived mesenchymal stem\/stromal cell in a microcarrier-based platform","volume":"8","author":"Moreira","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"936074","DOI":"10.3389\/fbioe.2022.936074","article-title":"Tips and tricks and clinical outcome of cryopreserved human amniotic membrane application for the management of medication-related osteonecrosis of the jaw (MRONJ): a pilot study","volume":"10","author":"Odet","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bone.2015.01.011","article-title":"Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model","volume":"74","author":"Ogata","year":"2015","journal-title":"Bone"},{"key":"B45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/medicina57050463","article-title":"Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ)","volume":"57","author":"Otto","year":"","journal-title":"Med. Kaunas."},{"key":"B46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oooo.2020.10.018","article-title":"Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study","volume":"131","author":"Otto","year":"","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.joms.2010.07.014","article-title":"Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study","volume":"69","author":"Pautke","year":"2011","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fbioe.2018.00105","article-title":"Tissue engineering and cell-based therapies for fractures and bone defects","volume":"6","author":"Perez","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","article-title":"Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages?","volume":"47","author":"Ristow","year":"2019","journal-title":"A long-term single-center cohort study"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4968724","DOI":"10.1155\/2016\/4968724","article-title":"Adipose derived-mesenchymal stem cells viability and differentiating features for orthopaedic reparative applications: banking of adipose tissue","volume":"2016","author":"Roato","year":"2016","journal-title":"Stem Cells Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.3390\/ijms24097948","article-title":"Immune dysfunction in medication-related osteonecrosis of the jaw","volume":"24","author":"Roato","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/jcm9061649","article-title":"Allogeneic bone marrow mesenchymal stem cell transplantation in tooth extractions sites ameliorates the incidence of osteonecrotic jaw-like lesions in zoledronic acid-treated rats","volume":"9","author":"Rodr\u00edguez-Lozano","year":"2020","journal-title":"J. Clin. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B54","doi-asserted-by":"publisher","first-page":"734562","DOI":"10.3389\/fcvm.2021.734562","article-title":"Latest advances in endothelial progenitor cell-derived extracellular vesicles translation to the clinic","volume":"8","author":"Salybekov","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13287-016-0390-4","article-title":"Combined transplantation of mesenchymal stem cells and endothelial progenitor cells for tissue engineering: a systematic review and meta-analysis","volume":"7","author":"Sun","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jbm.a.32142","article-title":"Composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation","volume":"90","author":"Usami","year":"2009","journal-title":"J. Biomed. Mater Res. A"},{"key":"B57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s10266-017-0295-4","article-title":"Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells","volume":"105","author":"Voss","year":"2017","journal-title":"Odontology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/scd.2015.0049","article-title":"Role of endothelial progenitor cells in maintaining stemness and enhancing differentiation of mesenchymal stem cells by indirect cell-cell interaction","volume":"25","author":"Wen","year":"2016","journal-title":"Stem Cells Dev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/SCS.0000000000009161","article-title":"Use of leukocyte-rich and platelet-rich fibrin (L-PRF) adjunct to surgical debridement in the treatment of stage 2 and 3 medication-related osteonecrosis of the jaw","volume":"34","author":"Yalcin-\u00dclker","year":"2023","journal-title":"J. Craniofac Surg."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5507\/bp.2020.023","article-title":"The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study","volume":"165","author":"Zelinka","year":"2021","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"B62","doi-asserted-by":"publisher","first-page":"606043","DOI":"10.3389\/fimmu.2021.606043","article-title":"The role of the immune response in the development of medication-related osteonecrosis of the jaw","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"8694","DOI":"10.3390\/ijms24108694","article-title":"Exosomes derived from adipose tissue-derived mesenchymal stromal cells prevent medication-related osteonecrosis of the jaw through IL-1RA","volume":"24","author":"Zheng","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1338376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:28:21Z","timestamp":1706243301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1338376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":63,"alternative-id":["10.3389\/fcell.2024.1338376"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1338376","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"article-number":"1338376"}}